ES2170858T3 - Derivados n-bencildioxotiazolidilbenzamidicos y procedimiento para la preparacion de los mismos. - Google Patents

Derivados n-bencildioxotiazolidilbenzamidicos y procedimiento para la preparacion de los mismos.

Info

Publication number
ES2170858T3
ES2170858T3 ES96920002T ES96920002T ES2170858T3 ES 2170858 T3 ES2170858 T3 ES 2170858T3 ES 96920002 T ES96920002 T ES 96920002T ES 96920002 T ES96920002 T ES 96920002T ES 2170858 T3 ES2170858 T3 ES 2170858T3
Authority
ES
Spain
Prior art keywords
groups
sup
carbon atoms
preparation
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96920002T
Other languages
English (en)
Inventor
Toshio Maeda
Masahiro Nomura
Katsuya Awano
Susumu Kinoshita
Hiroya Satoh
Koji Murakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2170858T3 publication Critical patent/ES2170858T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE NUEVOS DERIVADOS DE N BENCILDIOXOTIAZOLIDILBENZAMIDA QUE MEJORAN LA RESISTENCIA A INSULINA Y PRESENTAN POTENTES EFECTOS HIPOGLUCEMICOS Y DE DISMINUCION DE LIPIDOS, Y PROCEDIMIENTOS PARA SU PREPARACION, Y TRATA DE DERIVADOS DE N RIZAN PORQUE ESTAN REPRESENTADOS POR LA FORMULA GENERAL (1) [EN LA CUAL R SUP,1} Y R SUP,2} DENOTAN DE FORMA IDENTICA O DIFERENTE ATOMOS DE HIDROGENO, GRUPOS ALQUILO INFERIOR DE 1 A 4 ATOMOS DE CARBONO, GRUPOS ALCOXI INFERIOR DE 1 A 3 ATOMOS DE CARBONO, GRUPOS HALOALQUILO INFERIOR DE 1 A 3 ATOMOS DE CARBONO, GRUPOS HALOALCOXI INFERIOR DE 1 A 3 ATOMOS DE CARBONO, ATOMOS DE HALOGENO, GRUPOS HIDROXILO, GRUPOS NITRO, GRUPOS AMINO QUE PUEDEN ESTAR SUSTITUIDOS CON UN GRUPO(S) ALQUILO INFERIOR DE 1 A 3 ATOMOS DE CARBONO, O HETEROANILLOS, O R SUP,1} Y R SUP,2} SE UNEN PARA FORMAR UN GRUPO METILENDIOXI, R SUP,3} DENOTA UN GRUPO ALCOXI INFERIOR DE 1 A 3 ATOMOS DE CARBONO, UN GRUPO HIDROXILO O UN ATOMO DE HALOGENO, Y LA LINEA DISCONTINUA INDICA UNDOBLE ENLACE O UN ENLACE SENCILLO JUNTO CON LA LINEA CONTINUA], Y PROCEDIMIENTOS PARA SU PREPARACION.
ES96920002T 1995-06-02 1996-05-30 Derivados n-bencildioxotiazolidilbenzamidicos y procedimiento para la preparacion de los mismos. Expired - Lifetime ES2170858T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15978195 1995-06-02
JP15313996A JP3144624B2 (ja) 1995-06-02 1996-05-24 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法

Publications (1)

Publication Number Publication Date
ES2170858T3 true ES2170858T3 (es) 2002-08-16

Family

ID=26481850

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96920002T Expired - Lifetime ES2170858T3 (es) 1995-06-02 1996-05-30 Derivados n-bencildioxotiazolidilbenzamidicos y procedimiento para la preparacion de los mismos.

Country Status (15)

Country Link
US (1) US6030990A (es)
EP (1) EP0846693B1 (es)
JP (1) JP3144624B2 (es)
KR (1) KR100456177B1 (es)
CN (2) CN1069901C (es)
AT (1) ATE212341T1 (es)
AU (1) AU698896B2 (es)
CA (1) CA2220698C (es)
DE (1) DE69618792T2 (es)
DK (1) DK0846693T3 (es)
ES (1) ES2170858T3 (es)
HU (1) HU225039B1 (es)
PT (1) PT846693E (es)
TW (1) TW400328B (es)
WO (1) WO1996038428A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
WO1997032863A1 (en) * 1996-03-08 1997-09-12 Torii Pharmaceutical Co., Ltd. Thiazolidine-2,4-dione derivatives
CZ2001965A3 (cs) 1998-09-17 2002-02-13 Bristol-Myers Squibb Company Lék pro oąetřování atherosklerózy nebo diabetes typu II, farmaceutická kombinace a její pouľití
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
KR100700304B1 (ko) * 1999-08-23 2007-03-29 교린 세이야꾸 가부시키 가이샤 치환된 벤질티아졸리딘-2,4-디온 유도체
KR100738245B1 (ko) * 1999-08-23 2007-07-12 교린 세이야꾸 가부시키 가이샤 치환된 벤질티아졸리딘-2,4-디온 유도체
EP1207156B1 (en) 1999-08-23 2005-05-18 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
WO2001014352A1 (en) * 1999-08-23 2001-03-01 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
HUP0202731A3 (en) * 1999-09-17 2003-10-28 Kyorin Seiyaku Kk O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
EP1243266A4 (en) * 1999-11-11 2007-03-07 Kyorin Seiyaku Kk SOLIDS PREPARATION FOR ORAL APPLICATION
MXPA02006156A (es) * 1999-12-22 2003-09-22 Metabasis Therapeutics Inc Nuevos profarmacos de bisamidato fosfonato.
ATE340168T1 (de) * 2000-02-01 2006-10-15 Kyorin Seiyaku Kk Alkalimetallsalz von thiazolidin-2,4-dion- derivaten
WO2001066549A1 (en) * 2000-03-07 2001-09-13 Kyorin Pharmaceutical Co., Ltd. Intermediate compounds
CN1426402A (zh) * 2000-04-25 2003-06-25 杏林制药株式会社 噻唑烷二酮衍生物的新颖的稳定晶体及其制法
AU2001274502A1 (en) * 2000-06-14 2001-12-24 Kyorin Pharmaceutical Co. Ltd. Process for the preparation of thiazolidinedione derivatives
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1354602B1 (en) * 2000-12-26 2006-10-04 Sankyo Company, Limited Medicinal compositions containing diuretic and insulin resistance-improving agent
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
JP4711600B2 (ja) * 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
SI1413331T1 (sl) * 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
CA2434488A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US20020147184A1 (en) * 2001-01-26 2002-10-10 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
DK1385548T3 (da) * 2001-01-26 2007-09-10 Schering Corp Kombinationer af sterolabsorptionsinhibitor(er) med (et eller flere) kardiovaskulære midler til behandling af vaskulære tilstande
EP1785144A3 (en) * 2001-01-26 2007-05-23 Shering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7253178B2 (en) 2001-03-28 2007-08-07 Eisai Co., Ltd. Carboxylic acids
US7244861B2 (en) 2001-03-30 2007-07-17 Eisai Co., Ltd. Benzene compound and salt thereof
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
WO2002096415A2 (en) * 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
EP1394147A4 (en) 2001-06-04 2007-10-24 Eisai R&D Man Co Ltd CARBOXYLENE DERIVATIVE AND A SALT OR AN ESTER CONTAINING MEDICINE
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7132415B2 (en) * 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
WO2003088962A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
US6821524B2 (en) * 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
CN1662487A (zh) 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
MXPA05012086A (es) * 2003-05-12 2006-02-22 Pfizer Prod Inc Inhibidores de benzamida del receptor p2x7.
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
AU2005258924A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-`1,2,4!-triazin-2-YK!benzamide derivatives with P2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid
JP2008504363A (ja) * 2004-06-29 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｐ２ｘ７受容体のベンズアミド阻害剤を利用する併用療法
JP2008504360A (ja) * 2004-06-29 2008-02-14 ファイザー・プロダクツ・インク ヒドロキシル保護された前駆体を脱保護することによる５−［４−（２−ヒドロキシ−プロピル）−３，５−ジオキソ−４，５−ジヒドロ−３ｈ−１，２，４−トリアジン−２−イル］−ベンズアミド誘導体の製造方法
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
KR100958831B1 (ko) * 2006-09-19 2010-05-24 주식회사유한양행 헤테로아릴피리미딘 유도체, 이들의 제조방법, 및 이들을포함하는 조성물
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NO302519B1 (no) * 1991-12-26 1998-03-16 Sankyo Co Tiazolidinforbindelser som inneholder en kinongruppe, og farmasöytisk preparat

Also Published As

Publication number Publication date
HUP9802565A2 (hu) 1999-04-28
CN1336366A (zh) 2002-02-20
CN1133627C (zh) 2004-01-07
PT846693E (pt) 2002-05-31
JPH0948771A (ja) 1997-02-18
CA2220698C (en) 2003-06-17
EP0846693A4 (en) 1999-03-03
KR100456177B1 (ko) 2004-12-30
CN1069901C (zh) 2001-08-22
CN1186489A (zh) 1998-07-01
AU5844696A (en) 1996-12-18
JP3144624B2 (ja) 2001-03-12
TW400328B (en) 2000-08-01
HU225039B1 (en) 2006-05-29
AU698896B2 (en) 1998-11-12
ATE212341T1 (de) 2002-02-15
DE69618792T2 (de) 2002-10-10
DE69618792D1 (de) 2002-03-14
CA2220698A1 (en) 1996-12-05
HUP9802565A3 (en) 2000-01-28
EP0846693B1 (en) 2002-01-23
WO1996038428A1 (en) 1996-12-05
US6030990A (en) 2000-02-29
KR19990022435A (ko) 1999-03-25
EP0846693A1 (en) 1998-06-10
DK0846693T3 (da) 2002-05-06

Similar Documents

Publication Publication Date Title
ES2170858T3 (es) Derivados n-bencildioxotiazolidilbenzamidicos y procedimiento para la preparacion de los mismos.
ITMI930699A1 (it) Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
BG99885A (en) Pyrene-pyridine derivatives
ES2101331T3 (es) Derivados de k-252a.
BR9808438A (pt) Composição de barra
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
ES2191769T3 (es) Derivados 3-espiro-indolin-2-ona como ligandos de los receptores de la vasopresina y/o de la ocitocina.
NO1997005I1 (no) Olanzapin
DK0751129T6 (da) Substituerede dihydrodibenzo(b,f)azepiner, fremgangsmåde til fremstilling deraf, deres anvendelse i behandlingen af nogle lidelser i centralnervesystemet og farmaceutiske sammensætninger indeholdende disse
NO20010539L (no) Behandling av avhengighet og avhengighet-relatert oppforsel
ES2052629T3 (es) Pirazolo(3,4-d)piridinas, procedimiento para su preparacion y utilizacion como medicamentos.
SV1994000028A (es) Nuevas sulfonilamino pirimidinas, ref. 10916 sv.
NO963996L (no) Naftalamider som sentralnervesystem-midler
BR9913975A (pt) Agentes farmacêuticos para o tratamento da doença de parkinson, adhd e microadenomas
AR002016A1 (es) Derivados de 3-fenilisoquinoleina-1-(2h)-ona, procedimiento para su preparacion y medicamento y composicion farmaceutica que los contienen.
DE60043775D1 (de) Verfahren zum identifizieren von präneoplastischen und neoplastischen stadien in säugern
DE60025639D1 (de) Substituierte diazepan
ATE282433T1 (de) Kationische kopolymere von vinylamine und vinylalkohol zur verabreichung von oligonukleotiden
DE60031663T8 (de) Flammschutzmittel, verfahren zu dessen herstellung und flammschutzmittelharzzusammensetzung dieses enthaltend
DE69711633D1 (de) Stabile derivate von ubiquinol, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung
ES2181787T3 (es) Derivados de la 3h-2,3-benzodiazepina sustituidos en posicion 3, y su su utilizacion como medicamentos
BR0112092A (pt) 2-aminoalquiltieno[2,3-d]pirimidinas
AR021502A1 (es) Uso de derivados de azabicicloalcanos n-sustituidos para el tratamiento de enfermedades del sistema central nervioso
ES2171183T3 (es) Analogos y conjugados de piperidina con procainamida y napa.
ATE102247T1 (de) Gamma-glutamylcysteintransferase, verfahren zu deren herstellung und deren verwendung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 846693

Country of ref document: ES